Hepoxilin analogs

ABSTRACT

Compounds of the general structure ##STR1## are disclosed, wherein X is O, C n , NH, or S, wherein n is 1, 2, 3 or 4; R1 is OH, CH 3 , CH 2  OH, N 3  or CH 2  N 3  ; R3 is H or CH 3  ; R5 is Y-R2, wherein Y is a six-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; R2 is C 1  -C 10  alkyl OH, C 1  -C 10  alkyl N 3  or COOR4, wherein R4 is H, a branched or unbranched C 1  -C 10  alkyl (including substituted alkyl radicals), cycloalkyl, preferably C 5  or C 6  cycloalkyl, or a five- or six-membered aryl radical (including substituted aryl radicals), i.e. R2 is COOH or an ester of R4; R6 is a seven-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; and . . . . . . indicates a single, double or triple bond. The compounds are analogs of hepoxilins and are used to modulate hepoxilin activity, for example in the control of inflammation or other processes mediated by intracellular calcium levels.

This is a Continuation of application Ser. No. 08/038,324, filed Mar. 29, 1993, now abandoned on Mar. 21, 1995.

BACKGROUND OF THE INVENTION

It has become increasingly clear that second messengers play an important role in maintaining homeostasis in a diverse number of metabolic processes. Calcium is an important member of the group of second messengers, and regulation of calcium has become a focal point for investigating and controlling metabolic pathways and pathological conditions that can result from the aberrant regulation of these pathways. Regulation is achieved by opening or closing gated ion channels. This results in a change in the intracellular ion concentration in either of two ways: 1) changing the voltage across the plasma membrane or 2) allowing a major influx of ions, both generating an intracellular response. Calcium-regulated cell signaling pathways regulate cellular functions such as inflammation and smooth muscle contraction.

Inflammation is the body's reaction to injury. The inflammatory response involves three stages: first, an increase of blood flow to the injured area; second, an increase of capillary permeability caused by the retraction of endothelial cells lining vessel walls; and third, leucocyte migration to the site of injury. The third stage, known as chemotaxis, is a complex process that results in phagocytosis of invading agents by certain types of leucocytes such as the neutrophil. The neutrophil plays a key role in the body's response in inflammatory events such as infection. Once having arrived at the site of inflammation, the neutrophil is "activated" and releases a plethora of oxidative enzymes, known as a respiratory burst, that aid in destroying the invasive agent. An increase in intracellular calcium is thought to be involved in the initiation of the events that result in respiratory burst.

One group of compounds that have been shown to increase the influx of intracellular calcium in neutrophils is the "hepoxilins". Hepoxilins are products of an arachidonic acid pathway and have been implicated in the mediation of inflammation and smooth muscle contraction by modulation of second messenger calcium in response pathways. Hepoxilins are biologically active hydroxy epoxide derivatives of arachidonic acid formed through the 12-lipoxygenase pathway (Pace-Asciak et al., J. Biol. Chem. 258: 6835-6840, 1983; Pace-Asciak, Biochim. Biophys. Acta 793: 485-488, 1984; Pace-Asciak et al., Prostaglandins 25: 79-84, 1983). They are formed from 12-HPETE, an unstable hydroperoxide derivative of arachidonic acid (Pace-Asciak, J. Biol. Chem. 259: 8332-8337, 1984; Pace-Asciak et al., Adv. Prostal. Throm. Leuk. Res. 11: 133-134, 1983). Two hepoxilins have been isolated: hepoxilin A₃ [ (S, R)-hydroxy-11(S),12(S)-epoxy-eicosa-5Z, 9E, 14Z-trienoic acid] and hepoxilin B₃ [10(S, R)-hydroxy-11(R),12(S)-epoxy-eicosa-5Z, 8Z, 14Z-trienoic acid]. The term "hepoxilin" was coined in an attempt to combine aspects of structure with their first, though not necessarily their most important, demonstrated biological activity of insulin release (Pace-Asciak and Martin, Prostgl. Leukotriene and Med. 16: 173-180, 1984).

Hepoxilin A3 epimers are represented as: ##STR2##

Hepoxilin B3 epimers are represented as: ##STR3##

Hepoxilins are probably formed wherever 12-lipoxygenase is present because 12-HPETE is actively transformed into the hepoxilins by a variety of ferriheme proteins. Hence, ferriprotoporphyrin and such containing groups in proteins catalyze this transformation (Pace-Asciak et al., Biolog. Oxidation Systems, Eds C.C. Reddy et al., Academic Press, New York, 725-735, 1990). Hepoxilins are formed by platelets (Bryant and Bailey, Prostaglandins 17: 9-18, 1979; Jones et al., Prostaglandins 16: 583-590, 1978), lung (Pace-Asciak et al., Biochim. Biophys. Acta 712: 142-145, 1982), pancreatic islets (Pace-Asciak and Martin, ibid. 1984), brain (Pace-Asciak, ibid. 1988), aorta (Laneuville et al., Biochim. Biophys. Acta 1084: 60-68, 1991) and neutrophils (Dho et al., Biochem. J. 266: 63-68, 1990). Hepoxilin B₃ has been isolated from marine red algae (Moghaddam et al., J. Biol. Chem. 265: 6126-6130, 1990) and hepoxilin A₃ has been detected in the Aplysia brain (Piomelli et al., Proc. Natl. Acad. Sci. USA 86: 1721-1725, 1989). Hepoxilins are also formed by the rat pineal gland (Reynaud et al., unpublished observations).

Hepoxilins have been shown to possess a variety of biological actions related to their ability to affect ion fluxes in the cell. Hepoxilins raise intracellular calcium in human neutrophils (Dho et al., Biochem. J. 266: 63-68, 1990), increase the transport of calcium across membranes (Derewlany et al., Can. J. Physiol. Pharmacol. 62: 1466-1469, 1984), stimulate the release of insulin (Pace-Asciak and Martin, ibid. 1984), and regulate the volume of human platelets through an effect on potassium channels in the cell (Margalit et al. 1993 Proc. Natl. Acad. Sci. USA, in press). Biological actions of the hepoxilins demonstrated so far include the potentiation of aortic and tracheal vasoconstriction (Laneuville et al, Br. J. Pharmacol. 105: 297-304, 1992; 107: 808-812, 1992), potentiation of vascular permeability (Laneuville and Pace-Asciak, Prostaglandins, Leukotrienes, Lipoxins and PAF. Ed. J. M. Bailey, Plenum Press New York: 335-338, 1991), modulation of second messenger systems (Nigam et al., Biochem. Biophys. Res. Comm. 171: 944-948, 1990), regulation of cell volume (Margalit et al. Proc. Natl. Acad. Sci. USA, 1993, in press) and modulation of neurotransmission (Carlen et al., Brain Res. 497: 171-176, 1989; Piomelli et al., Proc. Natl. Acad. Sci USA 86: 1721-1725, 1989; and Pace-Asciak et al., Proc. Natl. Acad. Sci. USA 87: 3037-3041, 1990).

In view of the role of the hepoxilins in regulating physiological processes, a means for regulating hepoxilin action is needed. Hepoxilin antagonists find utility in reducing inflammation, asthma, hypertension, migraine and septic shock and in modulating other processes mediated by cellular calcium levels. Hepoxilin agonists find utility in diabetes.

BRIEF DESCRIPTION OF THE DRAWING

The FIGURE illustrates a synthetic scheme for certain hepoxilin analogs.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides hepoxilin analogs that modulate the mobilization of intracellular calcium in human neutrophils induced by such agonists as f-Met-Leu-Phe (fMLP), platelet activation factor (PAF), leukotriene B₄ (LTB4), hepoxilin A₃ and thapsigargin. Certain of these analogs (including 11,12-cyclopropyl analogs) have been found to antagonize hepoxilin activity in experimental models. As such they may be useful in the modulation of hepoxilin-mediated (or hepoxilin agonist-mediated) processes, including inflammation associated with neutrophil activation in inflammatory disease.

Broadly speaking, the present invention is directed to hepoxilin analogs having the general structure I or II: ##STR4## Within structures I and II: X is O, C_(n), NH, or S, wherein n is 1, 2, 3 or 4; R1 is OH, CH₃, CH₂ OH, N₃ or CH₂ N₃ ; R3 is H or CH₃ ; R5 is Y-R2, wherein Y is a six-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; R2 is C₁ -C₁₀ alkyl OH, C₁ -C₁₀ alkyl N₃ or COOR4, wherein R4 is H, a branched or unbranched C₁ -C₁₀ alkyl (including substituted alkyl radicals), cycloalkyl (including substituted cycloalkyl), preferably C₅ or C₆ cycloalkyl, or a five- or six-membered aryl radical (including substituted aryl radicals), i.e. R2 is COOH or an ester of R4; R6 is a seven-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; and . . . . . . indicates a single, double or triple bond; subject to the limitation that when the structure is ##STR5## and R2 is COOH or COOCH₃, then X is not O.

Within one embodiment, the hepoxilin analogs of the present invention are of the following structures III-IV: ##STR6## wherein structures V-VI are preferred: ##STR7## Within structures III-VI, R1, R2, R3, R4 and X are as previously defined, subject to the limitation that if R1 is OH, R2 is COOH or COOCH₃, and R3 is H, then X is not O. Preferred substitutions within R4 include lower alkyl and halo.

Unless otherwise specified, the term "alkyl" is used herein to refer to branched and unbranched alkyl radicals. Suitable alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-amyl, sec-amyl, n-hexyl, 2-ethylbutyl, 2,3-dimethylbutyl and the like. Lower alkyl (C₁ -C₆ alkyl) radicals are preferred, such as methyl and ethyl radicals. The term "alkenyl" refers to branched and unbranched hydrocarbon chains having one or more double bonds, including mono-unsaturated and poly-unsaturated radicals. Lower alkenyl radicals having from one to six carbon atoms are preferred. The term "alkynyl" refers to branched and unbranched hydrocarbon chains having one or more triple bonds, including mono-unsaturated and poly-unsaturated radicals. Lower alkynyl radicals having from one to six carbon atoms are preferred. The term "aryl" includes monocyclic aromatic hydrocarbon radicals. Suitable aryl groups include phenyl, chlorophenyl, benzyl and the like. The term "halo" includes chloro, fluoro, bromo and iodo. The symbol . . . . . . is used to indicate a bond that can be single, double or triple.

Preferred epimers of hepoxilin analogs III-VI include the following: ##STR8##

Within the compounds represented by structures III-XIV, X is preferably NH, S or C_(n), wherein n is 1, 2, 3 or 4; R1 is OH, CH₃, CH₂ OH, N₃ or CH₂ N₃ ; R2 is COOH or COOCH₃ ; and R3 is H, CH₃ OR CH₂ OH. When X is C_(n), X and carbon atoms 11 and 12 will form a three- to six-membered ring, optionally containing one or more double bonds, or an aromatic ring. Within these molecules it is particularly preferred that R1 is OH; X is C_(n), wherein n is most preferably 1, forming a cyclopropane ring; and R3 is H.

Within another preferred group of molecules, X is C_(n), NH or S; R1 is OH; R2 is COOR4; R3 is H or CH₃ ; and R4 is H or lower alkyl, particularly methyl. Particularly preferred compounds within this group are those in which R1═OH; X═CH₂ ; R2═COOH or COOCH₃ ; and R3═H, including those molecules designated as HA-921, HA-922, HA-923 and HA-924. ##STR9##

Within another preferred group of molecules, X is O and R2 is alkyl N₃, alkyl OH, an ester of a C₅ -C₁₀ alkyl radical, or an ester of an aryl radical, particularly an ester of a substituted or unsubstituted phenyl radical. Particularly preferred molecules within this group are those in which R2 is alkyl N₃ or alkyl OH, such as lower alkyl N₃ or lower alkyl OH.

According to the present invention, structural analogs of hepoxilins, including the representative hepoxilin antagonists methyl 8-hydroxy-11,12-cyclopropyl-5(Z), 9(E),14(Z)-eicosatrienoate (ΔHxA₃) and methyl 10-hydroxy-11,12-cyclopropyl-5(Z),8(Z),14(Z)-eicosatrienoate (ΔHxB₃), may conveniently be synthesized utilizing the acetylenic approach to hepoxilins (Demin et al., Bioorg. Khim 16:1125-1133, 1990).

A synthetic scheme for hepoxilin antagonists is set forth in the FIGURE. As shown therein, 1-hydroxyundeca-2(E)-en-5-yne (1), a common intermediate in this synthetic scheme, prepared as described (Demin et al., ibid.), is modified to obtain the corresponding three-membered cyclopropane ring- containing alcohols, which are the key synthons to hepoxilin analogs. According to this scheme, alcohol (1) [1-Hydroxyundeca-2(E)-en-5-yne] is treated with CH₂ I₂ and Zn-Cu couple in dry ether giving racemic (2S*,3S*)-2,3-cyclopropylalcohol (2), which is then oxidized to aldehyde (3) with pyrydinium dichromate. Two subsequent condensations of aldehyde (3) with Li-derivative of propargyl chloride leads to cyclopropylcarbinol (4). ¹ H-NMR spectrum at this stage shows a 7:3 ratio between two diastereomers. Propargylic chloride (4) is reacted with methyl hexynoate in the presence of equimolar amounts of CuI and NaI in DMF in the presence of K₂ CO₃, 10 hours at 20° C., resulting in the triacetylenic analog of ΔHxB₃ (5) obtained as an inseparable mixture with the same epimeric ratio. Following selective hydrogenation of the triacetylenic analog (5) on Lindlar catalyst in the presence of 2 equivalents of quinoline and subsequent separation, two C¹⁰ -epimers of more and less polar ΔHxB₃ methyl esters (6a,b) are obtained in a 7:3 ratio as a colorless oil. The same ratio between more and less polar epimers is obtained for native HxB₃ methyl esters when similar condensations of appropriate aldehyde with Li-derivative of terminal acetylene are used (Demin et al., ibid.]. The same relative configuration for more and less polar ΔHxB₃ is thus expected. This proposition is confirmed by the consideration of NMR spectra of individual ΔHxB₃ methyl esters (6a, 6b). NMR spectra show the two differences between epimers: coupling constant J₁₀,11 is larger for the more polar epimer (d, 7.8 Hz) than for the less polar epimer (d, J 7.3 Hz), and proton at C¹¹ of cyclopropyl group has less chemical shift (0.68 ppm) for the more polar epimer than for the less polar epimer (0.81 ppm). These data are in agreement with those described for α,β-cyclopropylcarbinolic systems (Descotes et al., Tetrahedron 29:2931-2935, 1973). Furthermore, oxidation of both fully saturated ΔHxB (ΔHxB₀) epimer and native saturated HxB (HxB₀) by pyrydinium dichromate into the corresponding ketones followed by treatment of the latter with sodium borohydride results, in both cases, in a mixture of initial α,β-cyclopropyl- and α,β-epoxycarbinols in a 1.7:1 ratio between less and more polar epimers. This ratio is similar to that described for reduction of α,β-epoxyketones to α,β-epoxycarbinols by NaBH₄ with preference of erythro- epoxycarbinol (Pierre et al., Tetrahedron Lett. (42): 4371-7374, 1972 and Nakata et al., Tetrahedron Lett. 22(47: 4723-4726, 1981).

On the basis of the foregoing considerations, it can be concluded that the more polar ΔHxB₃ epimer (6a) has a threo, syn or (10S*,11R*,12S*)-configuration, and the less polar epimer of ΔHxB₃ (6b) has a relative erythro, anti or (10R*,11R*,12S*)-configuration. In the case of cyclopropyl analogs of HxB₃, the absolute configuration of the carbinolic center is opposite to the configuration of native HxB₃, while the relative configuration remains the same (Demin et al., Bioorg. Khim. 16: 1125-1133, 1990).

To obtain the two C⁸ -epimeric ΔHxA₃ methyl esters (7a,b), the stereocontrolled rearrangement of allylic acetates catalyzed by Pd(II) (Grieco et al., J. Am. Chem. Soc. 102: 7587-7588, 1980) is used. Treatment of individual ΔHxB₃ acetates (8a, 8b) obtaining from (6a, 6b) with 0.1 eq. of PdCl₂ (MeCN)₂ in THF leads to the mixtures of ΔHxB₃ and ΔHxA₃ acetates (8a, 9a) and (8b, 9b) in a ca. 1:1 ratio in both cases. These acetates can be separated from each other by high performance liquid chromatography (HPLC) on a straight phase column (μ Porasil or the like) using 0.3% isopropanol in hexane. Subsequent hydrolysis gives two individual C⁸ -epimers of ΔHxA₃ (7a, 7b). On the basis of the S_(N) 2' reaction mechanism, the more polar ΔHxA₃ (obtained from anti ΔHxB₃) is referred to as syn or (8R*,11S*,12S*)-epimer (7b), and the less polar ΔHxA₃ as anti or (8S*,11S*,12S*)-epimer (7a), respectively. The chromatographic properties of ΔHxA₃ methyl esters (7a), (7b) are also similar to native HxA₃ methyl esters with known relative configuration (Demin et al., Bioorg. Khim., 16: 571-572, 1990 and Corey et al., Tetrahedron Lett.: 31(15): 2113-2116, 1990).

The above-described procedures are modified as necessary to produce other hepoxilin analogs. The necessary alterations in starting materials, reactants and conditions will be evident to those skilled in the art. Thus, the methods described above can be employed for the production of hepoxilin analogs having alternative R groups and different degrees of saturation at specific carbon atoms. Individual epimers or mixtures may be produced as desired.

Within the present invention, hepoxilin analogs may be prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids. Examples of such salts include organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid, tris hydroxy amino methyl (THAM) and the like. Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulfuric and phosphoric acids and the like. The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.

The compounds of the present invention find utility in human and veterinary medicine for modulating the action of the hepoxilins. Hepoxilin antagonists may be administered for the treatment of such conditions as inflammation, asthma, hypertension, migraine and septic shock. In general, the compounds or their salts are formulated for enteral or parenteral administration by combining them with a pharmaceutically acceptable vehicle according to conventional procedures. See, Remington's Pharmaceutical Sciences, 18th ed., Gennaro, ed., Mack Publishing Co, Easton, Pa., 1990, incorporated herein by reference. The active ingredient will be combined with one or more diluents, fillers, emulsifiers, excipients, etc., and may be provided in such forms as liquids, powders, emulsions, tablets, capsules and the like. Such compositions may further include one or more auxiliary substances, including wetting agents, preservatives, stabilizers, buffers, lubricants, colorings, etc.

The following non-limiting examples are provided to illustrate certain embodiments of the invention.

EXAMPLE I Instruments and Reagents

Referring to the FIGURE, vacuum distillation of compound (2) was done using a Kugelrohr apparatus (Aldrich, Milwaukee, Wis.) at the stated oven temperature. Thin layer chromatography was performed on aluminum sheets coated with silica gel 60 F₂₅₄, layer thickness 0.2 mm (Merck, Dharmstadt, Germany). Preparative HPLC was performed using a μ Porasil SiO₂ column, 7.8×300 mm (Waters, Milford, Mass.), using as eluent 0.8% i-PrOH in hexane for compounds (6a,b) and (7a,b), 0.3% i-PrOH in hexane for (8a,b) and (9a,b). GC analyses were carried out on a Hewlett-Packard 5700A gas chromatograph (Hewlett-Packard, Palo Alto, Calif.) using a glass capillary column, (SPB-1, Supelco, Bellefonte, Pa.) 60 m×0.3 mm. Electron impact mass spectra were obtained on a Hewlett-Packard GC MS using a fused silica methyl silicone capillary column (HP-1, 12 m×0.2 mm). Compounds (4), (5), (6a,b) and (7a,b) were injected onto the GC column as their tBDMSi derivatives prepared with a t-butyldimethylsilylimidazole-DMF kit (Supelco). ¹ H-NMR spectra were obtained on Bruker-AM500 (500 MHz) spectrometer (Bruker, Karlsruhe, Germany) in CDCl₃ with Me₄ Si as an internal standard (δ=0).

Pyridinium dichromate, Lindlar catalyst (Aldrich) and n-BuLi solution in hexane (Fluka, Buchs, Switzerland) were used as received. 1-Hydroxyundec-2(E)-en-5-yne (1) and 5-hexynoic acid were synthesized as described (Demin et al., Bioorg. Khim. 16: 1125-1133, 1990).

(2S*,3S*)-1-Hydroxy-2,3-Cyclopropyl-5-Yne (2)

A suspension of Zn-Cu couple (2.9 g) in dry ether (10 mL) in the presence of I₂ (0.1 g) was refluxed for 5 min until the red-brown color disappeared. Diiodomethane (2.95 g) was added, and the resulting mixture was stirred 1 h at 35° C. 1-Hydroxyundec-2(E)-en-1-yne (1; numbers refer to the synthetic scheme shown in the FIGURE) (0.33 g) in 5 mL of ether was added, and the reaction mixture was refluxed for 30 min with stirring. Saturated aqueous NH₄ Cl was added, the mixture was extracted with ether, and the ether phase was dried over Na₂ SO₄. After evaporation of the solvent, the residue was distilled in vacuo, yielding 279 mg (78%) of cyclopropyl alcohol (2), b.p. 100°-110° C. (10⁻² mm Hg). ¹ H-NMR (500 MHz, δ, ppm): 0.43, 0.53 (dt, 1H, J 4.9 and 8.5 Hz, cyclopropyl-H), 0.84, 1.05 (m, 2H, H² +H³), 0.90 (t, 3H, J 7.0 Hz, H¹¹), 1.33 (m, 4H, H⁹ +H¹⁰), 1.48 (quintet, 2H, J 7.22 Hz, H⁸), 2.14 (tt, 2H, J 2.4 and 7.2 Hz, H⁷), 2.19 (dt, 0.5 H, J 2.4 and 6.0 Hz, H⁴), 2.23 (dt, 0.5 H, J 2.4 and 6.0 Hz, H⁴), 2.32 (dt, 0.5 H, J 2.4 and 5.5 Hz, H⁴), 2.35 (dt, 0.5 H, J 2.4 and 5.5 Hz, H⁴), 3.46 (m, 2H, H¹). Mass spectrum (m/z, % of related intensity): 162 ([M-H₂ O]⁺, 0.4) 109 ([M-C₄ H₉ ]⁺, 25), 95 ([M-C₅ H₁₁ ]⁺, 34), 91 ([M-C₄ H₉ -H₂ O]⁺, 67), 79 (100 ), 77 ([M-C₅ H₁₁ -H₂ O]⁺, 52).

(2R*,3S*)-2,3-Cyclopropyl-5-Yn-1-Al (3)

To a suspension of Py₂ H₂ Cr₂ O₇ (85 mg) and molecular sieves 3 Å (Aldrich) (120 mg) in 3 mL of dry CH₂ Cl₂, 10 μl of AcOH and cyclopropyl alcohol (2) in 0.5 mL of CH₂ Cl₂ was added. After 30 min, the reaction was quenched by addition of 20 μl of isopropanol, and the mixture was filtered through silica gel and eluted with hexane. Evaporation of the solvent gave 18.2 mg (92%) of aldehyde (3). ¹ H-NMR (500 MHz, δ, ppm): 0.89 (t, 3H, J 6.9 Hz, H¹¹), 1.15, 1.30 (m, 2H, cyclopropyl-H), 1.33 (m, 4H, H⁹ +H¹⁰), 1.48 (quintet, 2H, J 7.1 Hz, H⁸), 1.65, 1.88 (m, 2H, H² +H³), 2.12 (tt, 2H, J 2.2 and 7.1 Hz, H⁷),.2.45 (m, 2H, H⁴), 9.13 (d, 1H, J 5.3 Hz, H¹). Mass-spectrum (m/z) % of related intensity): 177 ([M-1]⁺, 0.4), 149 ([M-CHO]⁺, 5.0), 121 ([M-C₄ H₉ ]⁺, 10), 107 ([M-C₅ H₁₁ ]⁺, 25), 93 ([M-C₄ H₉ -CHO+H]⁺, 29), 79 ([M-C₅ H₁₁ -CHO+H]⁺, 47) 69 (100).

(4S*, 5R*, 6S*)- and (4R*, 5R*, 6S*)-1-Chloro-4-Hydroxy-5,6-Cyclopropyltetradeca-2,8-Diynes (4)

A solution of propargyl chloride (1.6 g) in dry ether (100 mL) was cooled to -78° C., and n-BuLi (1.38 g, 21.6 mL of 1.5M in hexane) was added over a period of 15 min. The mixture was stirred for 30 min at -78° C., and aldehyde (3) (0.77 g) in 20 ml of ether was added. After 15 min, 20 ml of H₂ O was added to quench the reaction, and the mixture was warmed to 20° C. The ether layer was separated, the residue was extracted with ether, the combined extracts were dried over Na₂ SO₄, and the solvent was evaporated to dryness resulting in an orange oil which was absorbed on a silica gel column. Elution with 10% EtOAc in hexane and solvent removal gave an epimer mixture of racemic α, β-cyclopropyl alcohols (4) as a colorless oil (0.91 g, 84%, epimer ratio 7:3 by ¹ H-NMR analysis); ¹ H-NMR (500 MHz, δ, ppm); 0.57-0.69 (m, 2H, cyclopropyl-H), 0.90 (t, 3H, J 7.1 Hz, H¹⁴), 1.03, 1.09 (m, 1H, H⁵), 1.19 (m, 1H, H⁶), 1.32 (m, 4H, H¹² +H¹³), 1.48 (quintet, 2H, J 7.2 Hz, H¹¹), 1.89 (d, 1H, J 6.4 Hz, OH), 2.13 (tt, 2H, J 7.2 and 2.4 Hz, H¹⁰), 2.22-2.40 (m, 2H, H⁷), 4.15 (t, 2H, J 2.3 Hz, H¹), 4.28 (m, 0.3H, H⁴), 4.35 (m, 0.7H, H⁴). Mass spectrum of the tBDMSi . derivative (m/z, % of related intensity): 365 ([M-1]⁺, 0.15), 331 ([M-Cl]⁺, 1.9), 309 ([M-t-Bu]⁺, 5.0), 275 ([M-t-Bu-Cl+H]⁺, 6.8) 199 ([M-Cl-tBDMSi]⁺, 24), 129 ([M-C₅ H₁₁ -Cl-t-BuMe₂ SiOH+H]⁺, 92), 128 (100).

Methyl (10S*, 11R*, 12S*)- and (10R*, 11R*, 12S*)-10-Hydroxy-11,12-Cyclopropyleicosa-5,8,14-Triynoates (5)

To a suspension of anhydrous CuI (490 mg), NaI (774 mg) and K₂ CO₃ (712 mg) in DMF (50 mL), the solutions of methyl 5-hexynoate (390 mg in 5 mL of DMF) and propargylic chloride (4) (650 mg in 5 mL of DMF) were successively added. The mixture was stirred overnight at 20° C., then saturated aqueous NH₄ Cl solution (200 mL) was added. After extraction with ether, the organic layer was dried by Na₂ SO₄, and the solvent was evaporated to dryness. Subsequent filtration of the resulting oil through silica gel (eluent 15% EtOAc in hexane) afforded triyne (5) as a yellow oil (740 mg, 84%, epimer ratio 7:3 by ¹ H-NMR analysis). ¹ H-NMR (500 mHz, δ, ppm): 0.57, 0.64 (m, 2H, cyclopropyl-H), 0.90 (t, 3H, J 7.0 Hz, H²⁰), 1.00-1.22 (m, 2H, H¹¹ +H¹²), 1.33 (m, 4H, H¹⁸ +H¹⁹), 1.48 (quintet, 2H, J 7.1 Hz, H¹⁷), 1.82 (quintet, 2H, J 7.2 Hz, H³), 2.13-2.25 (m, 6H, H⁴ +H¹³ +H¹⁶), 2.44 (t, 2H, J 7.44 Hz, H²), 3.15 (quintet, 0.8H, J 2.3 Hz, H⁷), 3.30 (br.t., 0.2H, J 2.3 Hz, H⁷), 3.68 (s, 3H, COOMe), 4.26 (dt, 0.3H, J 6.4 and 1.3 Hz, H¹⁰), 4.32 (dt, 0.7H, J 6.1 and 1.9 Hz, H¹⁰). Mass spectrum of the tBDMS derivative (m/z, % of related intensity): 455 ([M-1]⁺, 0.15), 425 ([M-OMe]⁺, 0.19), 399 ([M-t-Bu]⁺, 37), 293 ([C¹⁰ -C²⁰ ]⁺, 3.7), 317 ([C⁸ -C²⁰ ]⁺, 0.90), 307 ([C¹ -C¹⁰ ]⁺, 0.80), 221 (64), 189 ([(C¹ -C¹¹)-t-BuMe₂ SiOH+H]⁺, 17), 75 (100).

Methyl (10S*, 11R*, 12S*)- and (10R*, 11R*, 12S*)-10-Hydroxy, 11,12-Cyclopropyl-5(Z),8(Z),14(Z)-Eicosatrienoates (6a,b)

A solution of triyne (5) (120 mg) in dry benzene (2 mL) was added to a mixture of hydrogenpresaturated Lindlar catalyst (100 mg) and quinoline (1000 μl) in 10 ml of benzene, and the resulting mixture was stirred until hydrogen consumption was completed (60 min, 10 mL of H₂ was absorbed). The poisoned catalyst was filtered off, and the filtrate was added to a new portion of hydrogen-presaturated Lindlar catalyst (100 mg) and quinoline (200 μl). After hydrogen consumption was stopped the procedure was repeated twice. During this procedure, the reaction mixture was analyzed by GC-MS as the tBDMSi derivative monitoring the prominent ion m/z 405 [M-t-Bu]⁺. After the reaction was completed (total hydrogen absorption 79.4 mL, 340% of theoretical amount), GC MS analysis of the reaction mixture showed 92% conversion into the desirable trienes (6a, b). The catalyst was filtered off, the filtrate was poured onto an aluminum oxide column (pH 6.9-7.1). Quinoline was removed with 5% EtOAc in hexane. The column was then eluted with EtOAc, giving a yellow oil (115 mg) containing 95% trienes (6a,b) (evaluated by GLC analysis of tBDMSi derivative). Individual epimers (6a), (6b) were separated using HPLC (μPorasil 7.8×300 mm, Waters), eluent 1.0% i-PrOH in hexane, UV- detection at 210 nm. More polar epimer (6a): a colorless oil, 55 mg yield (46%). Rf 0.39 (C₆ H₆ -Et₂ O, 85:15, 3 developments), ¹ H-NMR-spectrum (500 MHz, δ, ppm): 0.39 (dt, 1H, J 4.8 and 8.1 Hz, cyclopropyl-H), 0.53 (dt, 1H, J 4.8 and 8.5 Hz, cyclopropyl-H), 0.68 (m, 1H, H¹¹), 0.83 (m, 1H, H¹²), 0.87 (t, 3H, J 6.8 Hz, H²⁰), 1.26-1.36 (m, 6H, H¹⁷ +H¹⁸ +H¹⁹), 1.63 (br. s., 1H, OH), 1.70 (quintet, 2H, J 7.5 Hz, H³), 1.90-2.12 (m, 6H, H⁴ +H¹³ +H¹⁶), 2.32 (t 2H, J 7.5 Hz, H²), 2.75 (m, 1H, H⁷), 2.86 (m, 1H, H⁷), 3.67 (s, 3H, COOMe) 3.95 (ddd, 1H, J 1.0, 7.8 and 7.8 Hz, H¹⁰), 5.36-5.50 (m, 6H, olefinic H). Mass spectrum, tBDMSi derivative (m/z, % of related intensity): 462 ([M]⁺, 0.06), 431 ([M-OMe]⁺, 0.80), 405 ([M-t-Bu]⁺, 37), 324 ([C¹ -C¹¹ ]⁺, 20), 211 (12), 169 (12), 105 (21), 75 (100). Less polar epimer (6b): a colorless oil, 30 mg yield (25%). R_(f) 0.51 (C₆ H₆ -Et₂ O, 85:15, 3 developments), ¹ H-NMR-spectrum (500 MHz, δ, ppm): 0.33 (dt, 1H, J 5.1 and 8.4 Hz, cyclopropyl-H), 0.43 (dt, 1H, J 5.1 and 8.4 Hz, cyclopropyl-H), 0.81 (m, 2H, H¹¹ +H¹²), 0.89 (t, 3H, J 6.7 Hz, H²⁰), 1.25-1.36 (m, 6H, H¹⁷ +H¹⁸ +H¹⁹), 1.58 (d, 1H, J 3.2 Hz, OH), 1.70 (quintet, 2H, J 7.4 Hz, H³), 1.96-2.10 (m, 6H, H⁴ +H¹³ +H¹⁶), 2.31 (t, 2H, J 7.4 Hz, H²), 2.74, 2.84 (m, 2H, H⁷), 3.67 (s, 3H , COOMe), 3.97 (ddd, 1H, J 3.0, 7.3, and 7.3 Hz, H¹⁰), 5.36-5.48 (m, 6H, olefinic H). Mass spectrum, tBDMSi derivative (m/z, % of related intensity): 462 (0.04), 431 (0.35), 405 (20), 334 (4.7), 324 (2.8), 215 (4.2), 211 (3.0), 169 (6.0), 105 (26), 75 (100).

Methyl (8S*, 11S*, 12S*)- and (8R*, 11S*, 12S*)-8-Hydroxy-11,12-Cyclopropyl-5(Z), 9(E), 14(Z)-Eicosatrienoates (7a, b)

A mixture of triene (6a), (6b) (10 mg of each epimer), acetic anhydride (150 μl), and pyridine (450 μl) was maintained at 20° C. overnight. The mixture was evaporated to dryness, and the residue was purified by HPLC using 0.8% i-PrOH in hexane as eluent. The resulting allylic acetates (8a), (8b) were treated separately with a catalytic amount of freshly prepared bis(acetonitrile)palladium(II) chloride (0.6 mg, 0.1 equiv) in dry THF (10 mL) during 3 h at 20° C. THF was evaporated, and the residue was passed through an Al₂ O₃ column (pH 6.9-7.1) using EtORc as eluent. The resulting yellow oil contained a mixture of acetates ΔHxA₃ (7a), (7b) and ΔHxB₃ (6a), (6b) (ratio 1.2:1 from more polar ΔHxB₃ (HA-922) epimer (6a) and 0.9:1 from less polar ΔHxB₃ (HA-921) epimer (6b) by HPLC analysis). Acetates were separated by HPLC using 0.3% i-PrOH in hexane as eluent, yield of (9a) was 5.8 mg, 58% (from more polar ΔHxB₃ (6a)), and (9b) was 3.8 mg, 38% (from less polar ΔHxB₃ (6b)); ΔHxA₃ acetates (9a), (9b) were non-separable from each other by HPLC or by TLC. ¹ H-NMR spectrum (any epimer, 500 MHz, δ, ppm): 0.57 (m, 2H, cyclopropyl-H), 0.80, 1.15 (m, 2H, H¹¹ and H¹²), 0.88 (t, 3H, J 6.91 Hz, H²⁰), 1.28-1.32 (m, 6H, H¹⁷ +H¹⁸ +H¹⁹), 1.69 (quintet, 2H, J 7.4 Hz, H³), 1.99-2.07 (m, 6H, H² +H⁴ +H¹⁶), 2.01 (s, 3H, OAc), 2.32 (m, 4H, H⁷ +H¹³), 2.37 (dt, 1H, J 7.0 and 7.2 Hz, H⁸), 3.67 (s, 3H, COOMe), 5.19 (dt, 1H, J 6.7 and 6 8 Hz, H⁶), 5.29 (dd, 1H, J 8.7 and 15.5 Hz, H¹⁰), 5.38 (m, 3H, H⁵ +H¹⁴ +H¹⁵), 5.44 (dd, 1H, J 7.2 and 15.5 Hz, H⁹). Hydrolysis of the resulting pure acetates (9a), (9b) (10% NaOH/H₂ O in THF, 5 h, 20° C.) followed by esterification by diazomethane provided diastereochemically pure ΔHxA₃ methyl esters (7a), (7b). More polar epimer of ΔHxA₃ (HA-924) (7b) (from less polar ΔHxB₃ (6b)): 5.1 mg yield (51%). R_(f) 0.46 (C₆ H₆ -Et₂ O, 85:15, 3 developments), mass spectrum of the tBDMSi derivative (m/z, % of related intensity): 431 ([M-OMe]⁺, 0.18), 405 ([M-t-Bu]⁺, 4.7), 351 ([C¹ -C¹² ]⁺, 0.18), 321 ([C⁸ -C²⁰ ]⁺, 100), 197 (62), 189 ([(C⁸ -C²⁰)-t-BuMe₂ SiOH, 17), 171 (27), 75 (79), 73 (83). Less polar epimer of ΔHxA₃ (HA-923) (7a) (from more polar ΔHxB₃ (6a)): yield is 3.3 mg (33%). R_(f) 0.50 (C₆ H₆ -Et₂ O, 85:15, 3 developments), mass spectrum of the tBDMSi derivative (m/z, % of related intensity): 431 (0.06), 405 (1.0), 351 (0.04), 321 (28), 197 (24), 189 (7.3), 171 (12), 75 (56), 73 (100).

EXAMPLE II

The ability of hepoxilin analogs to inhibit agonist-evoked changes in the free intracellular calcium concentration of human neutrophils was assayed.

Human neutrophils were separated from fresh human blood by dextran sedimentation followed by centrifugation on either a Ficoll-Hypaque gradient (Boyum, J. Clin. Invest. 21:77-98, 1968) or a discontinuous plasma-Percoll gradient (Downey et al., J. Appl. Physiol. 64:728-741, 1988). Residual red blood cells were removed by lysis with NH₄ Cl and centrifugation. Washed cells were maintained at room temperature in RPMI 1640 (Sigma Chemical Co., St. Louis, Mo.) without HCO₃ ⁻ (buffered to pH 7.3 using 10 mM-Na Hepes) at 10⁷ cells/ml until assayed. For assaying, cells [(1-2)×10⁷ cells/ml] were suspended in medium containing NaCl (140 nM), KCl (5 nM), MgCl₂ (1 nM), CaCl₂ (1 nM), Hepes (10 nM) and glucose (10 nM), pH 7.3. The osmolarity of the media was adjusted to 290±5 mosm.

Intracellular free calcium was measured using the fluorescent indicator Indo-1-AM (Molecular Probes, Inc., Eugene, Oreg.). One ml of the freshly prepared neutrophil suspension (10 million cells) was loaded with 3 μl of a 1 mM solution of Indo-1-AM in DMSO (final concentration of the dye being 3 μM) for a period of 30 minutes at 37° C. Tubes were inverted every five minutes. The acetoxymethyl ester (AM) group on the dye allowed its penetration into the cell where esterases cleave it (by saponification) to release the free acid form which is trapped inside the cell. Unloaded dye was removed by centrifugation, and the cells were resuspended in fresh RPMI 1640 (Sigma Chemical Co.). Dye-loaded cells were kept at room temperature on a rotator. For each measurement, 2×10⁶ cells were added to 1 ml of a clear medium (composition in mM: NaCl 140, KCl 5, MgCl₂ 1, CaCl₂ 1, Hepes sodium free 10 and glucose 10, pH 7.3, osmolarity 290±5) in a temperature-controlled plastic cuvette (Diamed Lab., Canada) at 37° C. The cell suspension was continuously stirred. Fluorescence was continuously monitored with a Perkin-Elmer fluorescence spectrophotometer, model 650-40 (Perkin-Elmer, Norwalk, Conn.) and recorded on an LKB model 2210 chart recorder (Pharmacia, Sweden) set at 2 cm/min. The excitation wavelength was set at 331 nm, the emission wavelength set at 410 nm, and slits of excitation and emission were set at 3 and 15 respectively. Temperature of the cuvette was maintained at 37° C.±2° C. with (at 37° C.) circulating underneath the cuvette. An equilibrium period of approximately 2 to 5 minutes was allowed before addition of various agents to have a flat baseline signal. Intracellular free calcium was calculated using the following formula: ##EQU1##

All fluorescence values were measured relative to an MnCl₂ -quenched signal determined as follows: 250 nM is the K_(d) of Indo-1-AM, F is the relative fluorescence measurement of sample. F_(max) was determined by exposing cells to the calcium ionophore ionomycin (Sigma Chemical Co.) at 10⁻⁶ M final concentration. After F_(max) was determined, MnCl₂ at 3 mM final concentration was added to totally quench the Indo-1-AM signal and F_(Mn) was obtained. F_(min) was obtained as follows: 1/12×(F_(max) -F_(Mn))+F_(Mn). Calibration was performed on each sample. Hepoxilin analogs HxA₃ and other agonists (fMLP, PAF, LTB₄ and thapsigargin) were added to the cuvette as a 1000× concentrate in DMSO. Hepoxilin analogs HA921-924 were tested first at three concentrations (0.05, 0.1 and 0.5 μg/ml) in DMSO or the DMSO vehicle alone, followed five minutes later by each of the agonists at one concentration, i.e. HxA₃, 3 μg/ml; FMLP, 1×10⁻⁹ M; LTB₄, 2 ng/ml; PAF, 1 ng/ml and thapsigargin, 100 ng/ml). Alteration of agonist response by the hepoxilin analogs was evaluated by comparison of response in the absence of analog (DMSO vehicle alone) with that observed in the presence of analog.

The results of the assays, shown in the Table, demonstrate that HA-921, HA-922 and HA-923 at the higher concentrations (1.4 μM) inhibit the stimulation of intracellular calcium induced by fMLP, LTB₄, hepoxilin A₃ and thapsigargin. The analog HA-924 is shown to inhibit hepoxilin A₃ and thapsigargin.

                  TABLE                                                            ______________________________________                                         Hepoxilin         free [Ca.sup.2+ ]i                                           analog            (nM)                                                         (μg/ml)                                                                            Agonist*   HA-921   HA-922 HA-923                                                                               HA-924                                 ______________________________________                                         0      fMLP       580      871    741                                          0.05   "          260      820    129                                          0.1    "          420      461    516                                          0.5    "          280      435    161                                          0      PAF        800      1307   645                                          0.05   "          980      1512   806                                          0.1    "          840      2000   806                                          0.5    "          440      615    1516                                         0      LTB.sub.4  520      nd     290                                          0.05   "          340      1076   548                                          0.1    "          580      nd      64                                          0.5    "          380      384    nd                                           0      HxA.sub.3  300      1333   1451  638                                    0.05   "          240      333    193   381                                    0.1    "          140      256    193   273                                    0.5    "          320      128    322    26                                    0      Thapsigargin                                                                              1460     948    774   835                                    0.05   "          840      1256   2354  361                                    0.1    "          940      1051   612   250                                    0.5    "          280      358    225    39                                    ______________________________________                                          *Agonist concentrations used were: FMLP, 1 × 10.sup.-9 M; PAF, 1         ng/mL; LTB.sub.4, 2 ng/mL; HxA.sub.3, 3 μg/mL; Thapsigargin, 100 ng/mL                                                                               

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be evident that certain changes and modifications may be practiced within the scope of the appended claims. For example, the synthetic methodology may be modified by the ordinarily skilled practioner to produce other hepoxilin analogs, the activity of which can be readily assayed. 

What is claimed is:
 1. A compound selected from the group consisting of: ##STR10## and pharmaceutically acceptable salts thereof, wherein: X is C_(n), NH, or S, wherein n is 1, 2, 3 or 4;R1 is OH, CH₃, CH₂ OH, N₃ or CH₂ N₃ ; R3 is H or CH₃ ; R5 is Y-R2, wherein Y is a six-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; R2 is C₁ -C₁₀ alkyl OH, C₁ -C₁₀ alkyl N₃ or COOR4; R4 is H, C₁ -C₁₀ alkyl, C₅ -C₆ cycloalkyl, or C₅ -C₆ aryl; R6 is a seven-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; and . . . . . is a single, double or triple bond.
 2. A compound according to claim 1 wherein R2 is alkyl N₃, alkyl OH or COOR4, wherein R4 is C₅ -C₁₀ alkyl or C₅ -C₆ aryl.
 3. A compound selected from the group consisting of: ##STR11## and pharmaceutically acceptable salts thereof, wherein: X is NH, S or C_(n), wherein n is 1, 2, 3 or 4;R1 is OH, CH₃, CH₂ OH, N₃ or CH₂ N₃ ; R2 is COOR4, C₁ -C₁₀ alkyl OH or C₁ -C₁₀ alkyl N₃ ; R3 is H or CH₃ ; R4 is H, C₁ -C₁₀ alkyl, C₅ -C₆ cycloalkyl or C₅ -C₆ aryl; and . . . . . is a single, double or triple bond.
 4. A compound according to claim 3 wherein X is C_(n), NH or S.
 5. A compound according to claim 3 wherein X is C_(n).
 6. A compound according to claim 3, wherein X is CH₂.
 7. A compound according to claim 3, wherein R1 is OH.
 8. A compound according to claim 3, wherein R3 is H.
 9. A compound according to claim 3, wherein R2 is COOH or COOCH₃.
 10. A compound according to claim 3 wherein said compound is ##STR12## or a pharmaceutically acceptable salt thereof.
 11. A compound according to claim 10 wherein said compound is ##STR13## or a pharmaceutically acceptable salt thereof.
 12. A compound according to claim 11 wherein X is C_(n), NH or S; R1 is OH; R₂ is COOH or COOCH₃ and R3 is H.
 13. A compound according to claim 3 wherein R4 is C₅ -C₁₀ alkyl, C₅ -C₆ cycloalkyl or C₅ -C₆ aryl.
 14. A compound according to claim 3 wherein X is O and R2 is alkyl N₃ or alkyl OH.
 15. A compound according to claim 3 wherein R2 is alkyl N₃ or alkyl OH.
 16. A compound selected from the group consisting of: ##STR14## and pharmaceutically acceptable salts thereof, wherein: X is NH, S or C_(n), wherein n is 1, 2, 3 or 4;R1 is OH, CH₃, CH₂ OH, N₃ or CH₂ N₃ ; R2 is COOR4; R3 is H or CH₃ ; and R4 is H or lower alkyl.
 17. A compound according to claim 16 wherein X is C_(n).
 18. A compound according to claim 17 wherein R1 is OH, R2 is COOH or COOCH₃, and R3 is H.
 19. A compound according to claim 16 wherein R1 is OH, R2 is COOH or COOCH₃, and R3 is H.
 20. A compound selected from the group consisting of: ##STR15## and pharmaceutically acceptable salts thereof.
 21. A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable vehicle. 